- Home
- ODV vs ORIC Comparison
ODV vs ORIC Comparison
Compare ODV & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ODV | ORIC |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | Canada | United States |
| Employees | 102 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 807.5M | 861.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ODV | ORIC |
|---|---|---|
| Price | $2.35 | $9.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $19.73 |
| AVG Volume (30 Days) | ★ 2.8M | 1.8M |
| Earning Date | 08-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.06 | $7.23 |
| 52 Week High | $4.80 | $14.93 |
Technical Indicators
Market Signals| Indicator | ODV | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 33.91 | 60.98 |
| Support Level | N/A | $7.60 |
| Resistance Level | $3.50 | $12.75 |
| Average True Range (ATR) | 0.14 | 0.54 |
| MACD | 0.00 | 0.21 |
| Stochastic Oscillator | 5.13 | 94.95 |
Price Performance
Historical ComparisonAbout ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company projects include Cariboo Gold Project, Tintic Project, and Exploration.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.